Reverse-payment agreements remain low
The Federal Trade Commission said the number of final patent settlements entered by drugmakers in fiscal year 2017 was close to the record high of fiscal year 2016. But those that...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch